- Home
- SHMD vs NTHI Comparison
SHMD vs NTHI Comparison
Compare SHMD & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHMD
- NTHI
- Stock Information
- Founded
- SHMD 1864
- NTHI 2008
- Country
- SHMD Germany
- NTHI United States
- Employees
- SHMD N/A
- NTHI N/A
- Industry
- SHMD
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- SHMD
- NTHI Health Care
- Exchange
- SHMD Nasdaq
- NTHI Nasdaq
- Market Cap
- SHMD 123.6M
- NTHI 142.5M
- IPO Year
- SHMD N/A
- NTHI N/A
- Fundamental
- Price
- SHMD $2.60
- NTHI $7.38
- Analyst Decision
- SHMD
- NTHI
- Analyst Count
- SHMD 0
- NTHI 0
- Target Price
- SHMD N/A
- NTHI N/A
- AVG Volume (30 Days)
- SHMD 19.6K
- NTHI 95.7K
- Earning Date
- SHMD 02-25-2025
- NTHI 01-01-0001
- Dividend Yield
- SHMD N/A
- NTHI N/A
- EPS Growth
- SHMD N/A
- NTHI N/A
- EPS
- SHMD N/A
- NTHI N/A
- Revenue
- SHMD $85,165,542.00
- NTHI $79,990.00
- Revenue This Year
- SHMD N/A
- NTHI N/A
- Revenue Next Year
- SHMD N/A
- NTHI N/A
- P/E Ratio
- SHMD N/A
- NTHI N/A
- Revenue Growth
- SHMD N/A
- NTHI 13.52
- 52 Week Low
- SHMD $1.86
- NTHI $4.11
- 52 Week High
- SHMD $5.17
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- SHMD N/A
- NTHI N/A
- Support Level
- SHMD N/A
- NTHI N/A
- Resistance Level
- SHMD N/A
- NTHI N/A
- Average True Range (ATR)
- SHMD 0.00
- NTHI 0.00
- MACD
- SHMD 0.00
- NTHI 0.00
- Stochastic Oscillator
- SHMD 0.00
- NTHI 0.00
About SHMD SCHMID Group N.V. Class A Ordinary Shares
Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").